INTRODUCTION {#sec1}
============

The advent of next-generation sequencing and progress in transcriptome analysis has revealed that a majority of transcripts are not protein-coding RNAs but rather noncoding RNAs (ncRNAs) ([@B1]). Among ncRNAs, long ncRNAs (lncRNAs) that are \>200 bases long have been reported to interact with DNA-binding proteins, such as chromatin-modifying complexes and transcription factors, and regulate gene expression through epigenetic alterations in the nucleus ([@B2], [@B3]) or to function as a molecular sponge in the cytoplasm ([@B4]). Recent studies have shown that lncRNAs play important roles in various aspects of tumor progression, such as metastasis and angiogenesis, partly under hypoxia ([@B2], [@B5]).

Angiogenesis plays an essential role in tumor growth and metastasis ([@B6], [@B7]). Cross talk between cancer cells and immune cells via cytokines enhances macrophage infiltration and inflammatory responses, promoting angiogenesis ([@B8]). Key angiogenic stimuli are vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs), and hepatocyte growth factor (HGF) ([@B9], [@B10]).

We previously reported that histone demethylase Jumonji C domain containing histone demethylase 1 homolog D (JHDM1D, also known as KDM7A) was highly induced in cancer cells under nutrient starvation and decreased tumor growth by regulating tumor angiogenesis ([@B11]); however, the specific lncRNAs potentially involved in angiogenesis under nutrient starvation stress are largely unknown.

In this study, we identified the nutrient starvation-responsive lncRNA JHDM1D antisense 1 (JHDM1D-AS1), which arises from the antisense strand of JHDM1D. We demonstrated the role of JHDM1D-AS1 in tumor progression using cancer cells stably expressing JHDM1D-AS1 and found that JHDM1D-AS1 increases tumor growth by regulating tumor angiogenesis and may lead to a poor prognosis.

RESULTS {#sec2}
=======

JHDM1D-AS1 is highly expressed in cancer cells and tumor tissues under nutrient starvation. {#sec2-1}
-------------------------------------------------------------------------------------------

We previously reported that JHDM1D regulates tumor growth and angiogenesis under nutrient starvation ([@B11]). Using chromatin immunoprecipitation sequencing (ChIP-seq) and formaldehyde-assisted isolation of regulatory element sequencing (FAIRE-seq) in nutrient-starved PANC-1 cells, we found a promoter antisense lncRNA, JHDM1D-AS1, sharing a common promoter that was characterized in the RefSeq database ([Fig. 1A](#F1){ref-type="fig"}) concomitant with the active histone mark of H3K27 acetylation and a nucleosome-free region ([Fig. 1A](#F1){ref-type="fig"}). Expression of JHDM1D and JHDM1D-AS1 was highly correlated in various cancer cell lines ([Fig. 1B](#F1){ref-type="fig"}). The expression of both JHDM1D and JHDM1D-AS1 was decreased by deletion of common 5′ promoter regions of JHDM1D and JHDM1D-AS1 using guide RNA (gRNA)-mediated genome editing ([Fig. 1C](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}), suggesting that JHDM1D and JHDM1D-AS1 share their promoter. JHDM1D was previously reported to be upregulated under nutrient starvation in various cancer cells ([@B11]); therefore, we hypothesized that JHDM1D-AS1 could also be upregulated under starvation. Expression of JHDM1D-AS1 and JHDM1D was commonly increased under nutrient starvation in the PANC-1 and AsPC-1 cell lines ([Fig. 1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). The expression of JHDM1D and JHDM1D-AS1 was also increased in other cancer cell lines, including HeLa cervical cancer cells, T98G glioblastoma cells, and SW620 colorectal cancer cells ([Fig. 1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). Expression of JHDM1D and JHDM1D-AS1 was increased in normal cells, including normal human dermal fibroblasts (NHDFs) and human umbilical vein endothelial cells (HUVECs) ([Fig. 1F](#F1){ref-type="fig"} and [G](#F1){ref-type="fig"}). We have previously reported that the mRNAs for nutrient starvation-responsive genes, including JHDM1D, the sense gene of JHDM1D-AS1 that is upregulated under nutrient starvation *in vitro*, were also upregulated *in vivo* in avascular tumor tissues ([@B11], [@B12]) To investigate whether RNA expression of JHDM1D-AS1 is increased in avascular tumor tissues *in vivo*, PANC-1 cells were inoculated in *scid/scid* mice, and tumor samples were obtained on day 0, day 3, day 5, and day 10 (*n* = 3 per each time point). We found that expression of JHDM1D and JHDM1D-AS1 was increased in avascular tumor tissue, especially on day 3 compared to day 5 and day 10 *in vivo* ([Fig. 1H](#F1){ref-type="fig"}). Thus, the nutrient starvation-induced upregulation of JHDM1D and JHDM1D-AS1 may be not specific to pancreatic cancer cells. Together these results suggest that JHDM1D-AS1 may play an essential role in cancer cells.

![JHDM1D-AS1 is coexpressed with JHDM1D under nutrient starvation. (A) JHDM1D-AS1 and JHDM1D share a promoter at chr 7. The histone H3K27ac marks and open chromatin region comprise the shared promoter. FAIRE-seq, H3K27Ac ChIP-seq, and RNA seq were conducted in PANC-1 cells under nutrient starvation (NS) in comparison to the nutrient-rich control (CON) conditions. (B) JHDM1D-AS1 RNA expression levels are highly correlated with JHDM1D levels in various cancer cell lines (the expression data were obtained from Affymetrix Exon array data obtained from our institutional database, RefExA \[<http://www.lsbm.org/site_e/database/index.html>\]). Pearson\'s correlation test was used (*P* \< 0.05 for significance; *r* = correlation coefficient). (C) CRISPR/Cas-mediated genomic deletion of the JHDM1D-AS1 promoter region downregulates the expression of both JHDM1D-AS1 and JHDM1D. A schematic of the genomic target regions is shown on the left. (D) The expression level of JHDM1D is increased in response to nutrient starvation in PANC-1, AsPC-1, HeLa, T98G, and SW620 cells. (E) The expression level of JHDM1D-AS1 is increased in response to nutrient starvation in PANC-1, AsPC-1, HeLa, T98G, and SW620 cells. (F) The expression level of JHDM1D is increased in response to nutrient starvation in fibroblastic NHDFs and endothelial HUVECs. (G) The expression level of JHDM1D-AS1 is increased in response to nutrient starvation in NHDFs and HUVECs. (H) The expression levels of JHDM1D and JHDM1D-AS1 are increased in the avascular tumor tissues from day 3 to day 5. Data are presented as the mean ± standard error of the mean (SEM) from at least three independent experiments. The expression of each transcript is reported relative to that of β-actin and was determined by real-time quantitative PCR (qPCR) analysis. Student\'s *t* tests were performed for the indicated comparisons (\*\*\*, *P* \< 0.005; §§§, *P* \< 0.005).](zmb9991015880001){#F1}

###### 

Promoter sequences deleted by guide RNAs

  gRNA set   Deleted sequence
  ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1          CGGCGCGCGCTCCCCGCTCCTCTCCGCGACGGCCGGGCGGAGGGAGCTGTTGAAGGGCACGCAGGCGGCTGCGGGGGCGGAGGGAGCTGGTGGCGGCGGGCGCGCGGCCGCAGCCGGAGGAGGACGGCGGGAGCGTGCGAGGAGCTGGCTCGGTTATTTCGGAGCGAGAGCCGAGGCCGGGGGAAGTTCCTGCGGAGTGCTCAAGGGCAGAAGAGGTGCCGCGTCCCGAAGAGGGGAAGCGGAGAAGTTTGCTGCTGCCCGGGTCGCCT
  2          CGGCGCGCGCTCCCCGCTCCTCTCCGCGACGGCCGGGCGGAGGGAGCTGTTGAAGGGCACGCAGGCGGCTGCGGGGGCGGAGGGAGCTGGTGGCGGCGGGCGCGCGGCCGCAGCCGGAGGAGGACGGCGGGAGCGTGCGAGGAGCTGGCTCGGTTATTTCGGAGCGAGAGCCG
  3          CGGCCGGGCGGAGGGAGCTGTTGAAGGGCACGCAGGCGGCTGCGGGGGCGGAGGGAGCTGGTGGCGGCGGGCGCGCGGCCGCAGCCGGAGGAGGACGGCGGGAGCGTGCGAGGAGCTGGCTCGGTTATTTCGGAGCGAGAGCCGAGGCCGGGGGAAGTTCCTGCGGAGTGCTCAAGGGCAGAAGAGGTGCCGCGTCCCGAAGAGGGGAAGCGGAGAAGTTTGCTGCTGCCCGGGTCGCCT

Overexpression of JHDM1D-AS1 increases cell growth *in vitro*. {#sec2-2}
--------------------------------------------------------------

JHDM1D-AS1 is an ∼2.4-kbp noncoding RNA without any splicing site, according to the RefSeq database ([NR_024451](https://www.ncbi.nlm.nih.gov/nuccore/NR_024451)). We examined the cellular localization of JHDM1D-AS1 by subcellular fractionation and reverse transcription-PCR (RT-PCR) of JHDM1D-AS1. We found that JHDM1D-AS1 was localized in both the cytoplasm and nucleus in PANC-1 and AsPC-1 cells, which is similar to the localization of coding mRNAs such as those encoding ACTB and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ([Fig. 2A](#F2){ref-type="fig"}). Other nucleus-retained lncRNAs, including MALAT1, Xist, and TUG1, showed nucleus-specific localization, as previously reported ([@B13]).

![JHDM1D-AS1 is localized in both the cytoplasm and nucleus and increases cell proliferation *in vitro*. (A) Subcellular localization of JHDM1D-AS1. PANC-1 and AsPC-1 cells were subjected to subcellular fractionation, and the amounts of JHDM1D-AS1 in each fraction were evaluated by quantitative real-time PCR. ACTB, BIRC5, S14, and GAPDH genes were used as cytoplasm and nuclear marker genes. MALAT1, Xist, and TUG1 were used as nuclear markers. (B) Expression of JHDM1D-AS1 is stably induced by retroviral transduction of JHDM1D-AS1 in PANC-1 and AsPC-1 cells. (C) The expression level of JHDM1D is not affected by JHDM1D-AS1 overexpression in PANC-1 and AsPC-1 cells. (D) Subcellular localization of JHDM1D-AS1 is not altered by JHDM1D-AS1 overexpression. (E) JHDM1D-AS1 overexpression slightly increased cell growth in control medium in PANC-1 and AsPC-1 cells. (F) JHDM1D-AS1 overexpression does not affect cell growth in nutrient starvation medium in PANC-1 and AsPC-1 cells. Data are presented as the mean ± SEM from at least three independent experiments. The expression of each transcript is reported relative to that of β-actin and was determined by real-time qPCR analysis. Student\'s *t* tests were performed for the indicated comparisons (\*\*\*, *P* \< 0.005).](zmb9991015880002){#F2}

To investigate the role of JHDM1D-AS1 in tumor progression, we generated PANC-1 and AsPC-1 cells expressing JHDM1D-AS1 by retroviral transduction. The stable expression of JHDM1D-AS1 did not affect mRNA expression of JHDM1D ([Fig. 2B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}). The subcellular localization of the overexpressed JHDM1D-AS1 was similar to that of endogenous JHDM1D-AS1 in both PANC-1 and AsPC-1 cells ([Fig. 2D](#F2){ref-type="fig"}). Overexpression of JHDM1D-AS1 slightly increased cell growth in PANC-1 and AsPC-1 cells under growth-rich conditions ([Fig. 2E](#F2){ref-type="fig"}) but had minor effects on cell growth under nutrient starvation conditions ([Fig. 2F](#F2){ref-type="fig"}) *in vitro*. These results suggest that JHDM1D-AS1 may be involved in the growth of cancer cells.

Induction of JHDM1D-AS1 significantly increases *in vivo* tumor growth by stimulating tumor angiogenesis and infiltration of CD11b^+^ monocyte/macrophage lineage cells. {#sec2-3}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Although JHDM1D-AS1 had minor effects on *in vitro* cell growth, we hypothesized that JHDM1D may play a role in *in vivo* tumor growth ([Fig. 2E](#F2){ref-type="fig"}). To investigate the role of JHDM1D-AS1 in *in vivo* tumor growth, 1 × 10^7^ JHDM1D-AS1-expressing PANC-1 and AsPC-1 cells were subcutaneously inoculated into C.B17/Icr-scidJcl *scid/scid* mice (*n* = 5). We confirmed that JHDM1D-AS1 overexpression was maintained *in vivo* and had no effect on JHDM1D expression ([Fig. 3A](#F3){ref-type="fig"}). Although JHDM1D-AS1 expression occurred at supraphysiological levels in JHDM1D-AS1-overexpressing cells, tumor growth was significantly increased in mice inoculated with both PANC-1-JHDM1D-AS1 and AsPC-1-JHDM1D-AS1 cells compared with that in the control cells ([Fig. 3B](#F3){ref-type="fig"}). To investigate the protumor effect of JHDM1D-AS1 *in vivo*, we examined tumor angiogenesis and infiltration of macrophages within tumor tissues by immunohistochemical analysis ([Fig. 3C](#F3){ref-type="fig"}). Formation of CD31^+^ blood vessels and infiltration of CD11b^+^ monocyte/macrophage lineage cells were significantly increased in tumor tissues ([Fig. 3D](#F3){ref-type="fig"} and [E](#F3){ref-type="fig"}), as reported previously ([@B11], [@B14]), suggesting that JHDM1D-AS1 may increase tumor growth by regulating angiogenesis.

![JHDM1D-AS1 overexpression increases tumorigenicity *in vivo* by inducing angiogenesis and macrophage infiltration. (A) Expression of JHDM1D-AS1 is maintained in tumor tissues derived from PANC-1 and AsPC-1 cells stably expressing JHDM1D-AS1 and has only a minor effect on JHDM1D expression in tumor tissues *in vivo*. (B) Overexpression of JHDM1D-AS1 in PANC-1 and AsPC-1 cells accelerates tumor growth *in vivo*. (C) Representative immunostaining images of tumor tissues derived from JHDM1D-AS1-overexpressing AsPC-1 cells compared to those derived from control AsPC-1 cells. (D) Quantitative analysis of CD31^+^ blood vessel density (pixels) in AsPC-1 cells. (E) Quantitative analysis of CD11b^+^ cells (counted-cell number) among AsPC-1 cells. Data are presented as the mean ± SEM from at least three independent experiments. The expression of each transcript is reported relative to that of β-actin and was determined by real-time qPCR analysis. Student\'s *t* tests were performed for the indicated comparisons (\*, *P* \< 0.05; \*\*\*, *P* \< 0.005).](zmb9991015880003){#F3}

To investigate whether silencing of JHDM1D-AS1 small interfering RNAs (siRNAs) influences cancer cell growth *in vitro* and tumor growth *in vivo*, we knocked down JHDM1D-AS1 using siRNA ([Fig. 4A](#F4){ref-type="fig"}). Although inhibition of JHDM1D-AS1 had minor effects on cell growth under growth-rich ([Fig. 4B](#F4){ref-type="fig"}) and nutrient starvation ([Fig. 4C](#F4){ref-type="fig"}) conditions in PANC-1 and AsPC-1 cells *in vitro*, inhibition of JHDM1D-AS1 significantly decreased the tumor growth of PANC-1 cells *in vivo* ([Fig. 4D](#F4){ref-type="fig"}).

![JHDM1D-AS1 knockdown decreased tumorigenicity *in vivo*. (A) Knockdown efficiency of siRNA against JHDM1D-AS1 *in vitro*. (B) JHDM1D-AS1 knockdown does not affect cell growth in the control medium in PANC-1 and AsPC-1 cells. (C) JHDM1D-AS1 knockdown does not affect cell growth under nutrient starvation in PANC-1 and AsPC-1 cells. (D) Depletion of JHDM1D-AS1 by siRNA in PANC-1 and PANC1 cells suppresses tumor growth *in vivo*. The expression of each transcript is reported relative to that of β-actin and was determined by real-time qPCR analysis. Student\'s *t* tests were performed for the indicated comparisons (\*, *P* \< 0.05; \*\*\*, *P* \< 0.005).](zmb9991015880004){#F4}

Induction of JHDM1D-AS1 increases angiogenesis by increasing levels of tumor-derived angiogenic factors and host-derived protumorigenic inflammation *in vivo*. {#sec2-4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate whether the angiogenic effects of the JHDM1D-AS1-expressing tumor were derived from regulation of angiogenic factors, mRNA expression in human cancer cells was compared between tumor xenografts comprising hJHDM1D-AS1-expressing AsPC-1 cells and xenografts comprising control AsPC-1 cells by using a human-specific microarray (i.e., Human Genome U133 plus 2.0 oligonucleotide array) ([Fig. 5A](#F5){ref-type="fig"}; see Table S1 in the supplemental material). We found that 1,400 genes were upregulated and 584 genes were downregulated in hJHDM1D-AS1-expressing AsPC-1 xenografts ([Fig. 5B](#F5){ref-type="fig"}). We next conducted a gene set enrichment analysis (GSEA) and found that angiogenic pathways were activated in cancer cells by JHDM1D-AS1 overexpression in tumor tissues *in vivo* ([Fig. 5C](#F5){ref-type="fig"}). We investigated the expression of major pro- and antiangiogenic factors by quantitative real-time PCR and found that human *HGF* and human *FGF1* were significantly upregulated in tumor xenografts comprising hJHDM1D-AS1-expressing PANC-1 cells and those comprising hJHDM1D-AS1-expressing AsPC-1 cells compared with xenografts comprising control cells ([Fig. 5D](#F5){ref-type="fig"}), suggesting that expression of JHDM1D-AS1 increases the expression of angiogenic factors in cancer cells. To investigate the effect of JHDM1D-AS1 on endothelial cell growth, we cultured either control or JHDM1D-AS1-overexpressing pancreatic (PANC-1 and AsPC-1) cells for 24 h under growth-rich and nutrient starvation conditions. Culture supernatants of either control or JHDM1D-AS1-overexpressing cells were concentrated and supplemented to the cell culture of HUVECs *in vitro*. The culture supernatant of JHDM1D-AS1-overexpressing pancreatic (PANC-1 and AsPC-1) cells under growth-rich conditions increased HUVEC growth for 72 h *in vitro* compared to that of empty-vector-treated control cells ([Fig. 5E](#F5){ref-type="fig"}). We additionally examined whether the culture supernatant of JHDM1D-AS1-overexpressing PANC-1 and AsPC-1 cells under starvation could stimulate HUVEC growth under starvation *in vitro*. We found that the culture supernatant of JHDM1D-AS1-overexpressing PANC-1 and AsPC-1 cells under nutrient starvation stimulated endothelial cell growth under nutrient starvation ([Fig. 5F](#F5){ref-type="fig"}), suggesting that JHDM1D-AS1 may stimulate endothelial cell growth under nutrient starvation.

![JHDM1D-AS1 overexpression increases the expression of genes for angiogenic factors such as *HGF1* and *FGF1* in cancer cells. (A) Schematic representation of microarray analysis. Expression of mRNA derived from cancer cells and stroma cells was separately examined by using human genome U133 plus 2.0 arrays and mouse genome 430 2.0 arrays, respectively. (B) Heat map representation of 1,983 human cancer cell-derived genes that were up- or downregulated by more than 2-fold *in vivo* in tumor tissues derived from JHDM1D-AS1-overexpressing AsPC-1 cells. (C) Angiogenesis-related genes are upregulated in tumor tissues derived from HDM1D-AS1-overexpressing AsPC-1 cells, as determined by GSEA analysis. (D) Expression of major proangiogenic and antiangiogenic factors in tumor tissues derived from JHDM1D-AS1-expressing PANC-1 and AsPC-1 cells. mRNA expression of proangiogenic and antiangiogenic factors was measured in PANC-1 and AsPC-1 cells by quantitative real-time PCR analysis. (E) Tumor supernatant from JHDM1D-AS1-overexpressing PANC-1 and AsPC-1 cells under the control condition induced endothelial cell growth. The proliferation of human umbilical vein endothelial cells (HUVECs) was measured with a mixture of EGM-2 and either RPMI (for PANC-1 cells) or DMEM (for AsPC-1 cells) culture supernatants. (F) Tumor supernatant from JHDM1D-AS1-overexpressing PANC-1 and AsPC-1 cells under the nutrient-starved condition induced endothelial cell growth. The proliferation of HUVECs was measured with a mixture of EGM-2 and either RPMI-NS (from PANC-1 cells) or DMEM-NS (from AsPC-1 cells) culture supernatants. Data are presented as the mean ± SEM for at least three independent experiments. The expression of each transcript is reported relative to that of β-actin and was determined by real-time qPCR analysis. Student\'s *t* tests were performed for the indicated comparisons (\*\*\*, *P* \< 0.005).](zmb9991015880005){#F5}

We next investigated the expression of host (mouse origin)-derived factors upon JHDM1D-AS1 overexpression ([Fig. 6A](#F6){ref-type="fig"}; see Table S2 in the supplemental material) by using mouse-specific microarrays for tumor xenografts comprising hJHDM1D-AS1-expressing AsPC-1 cells. We identified 1,560 transcripts that were up- or downregulated by more than 2-fold ([Fig. 5A](#F5){ref-type="fig"} and [6A](#F6){ref-type="fig"}). GSEA analysis indicated that host genes related to NF-κB inflammation signaling were upregulated in tumor tissues of mice inoculated with JHDM1D-AS1-expressing AsPC-1 cells ([Fig. 6B](#F6){ref-type="fig"}). Expression levels of host-derived m*Mmp3*, m*Mmp9*, m*S100a8*, and m*S100a9* were significantly increased in tumor xenografts comprising hJHDM1D-AS1-expressing AsPC-1 and PANC-1 cells compared with those comprising control cells ([Fig. 6C](#F6){ref-type="fig"}). We and others previously reported that expression of host-derived m*Mmp3*, m*Mmp9*, m*S100a8*, and m*S100a9* increases angiogenesis *in vivo* ([@B15], [@B16]). These data suggest that JHDM1D-AS1 promotes angiogenesis by regulating multiple tumor-derived angiogenic factors and host-derived proangiogenic inflammatory genes, resulting in tumor progression.

![JHDM1D-AS1 overexpression triggers inflammation and upregulation of genes for proinflammatory factors such as *MMP3*, *MMP9*, *S100a8*, and *S100a9* in host-derived cells in tumor tissues. (A) Heat map representation of 1,559 mouse genes that were up- or downregulated by more than 2-fold in tumor tissues derived from JHDM1D-AS1-overexpressing AsPC-1 cells *in vivo*. (B) Mouse genes related to tumor necrosis factor alpha (TNF-α) signaling via NF-κB are upregulated in tumor tissues of mice inoculated with JHDM1D-AS1-expressing AsPC-1 cells. (C) Expression of genes for mouse proinflammatory factors such as m*Mmp3*, m*Mmp9*, m*S100a8*, and m*S100a9* is increased in tumor tissue derived from JHDM1D-AS1-expressing PANC-1 and AsPC-1 cells. Data are presented as the mean ± SEM from at least three independent experiments. The expression of each transcript is reported relative to that of β-actin and was determined by real-time qPCR analysis. Student\'s *t* tests were performed for the indicated comparisons (\*\*\*, *P* \< 0.005).](zmb9991015880006){#F6}

JHDM1D-AS1 is highly expressed in tumor tissues and contributes to malignancy. {#sec2-5}
------------------------------------------------------------------------------

Because JHDM1D-AS1 increased *in vivo* tumor growth in mice ([Fig. 3](#F3){ref-type="fig"}), we hypothesized that the JHDM1D-AS1 may contribute to cancer progression, including overall survival, in patients. We found that JHDM1D-AS1 expression was highly increased in various cancer cell lines and cancer patient samples compared to that in normal cells and tissues ([Fig. 7A](#F7){ref-type="fig"}).

![JHDM1D-AS1 is highly expressed in various cancer patients and correlates with poor prognosis. (A) The JHDM1D-AS1 expression level is elevated in various cancer cell lines and clinical samples from cancer patients (the expression data were obtained from Affymetrix Exon array data from our institutional database RefExA \[<http://www.lsbm.org/site_e/database/index.html>\]). (B) Kaplan-Meier plots for estimation of overall survival of patients with 330 bladder urothelial carcinoma (BLCA), 236 cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), 163 glioblastoma multiforme (GBM), 595 kidney renal clear cell carcinoma (KIRC), 365 liver hepatocellular carcinoma (LIHC), 490 lung adenocarcinoma (LUAD), 468 lung squamous cell carcinoma (LUSC), 152 pancreatic adenocarcinoma (PAAD), 290 skin cutaneous melanoma (SKCM), and 344 stomach adenocarcinoma ([@B17]) samples. Patients were classified into two groups, high risk and low risk, by the Lasso-regularized Cox proportional-hazard model based on expression profiles of JHDM1D-AS1 direct or indirect target genes (JHDM1D-AS1 signature).](zmb9991015880007){#F7}

To further evaluate the prognostic effects of JHDM1D-AS1 on overall survival in cancer patients, we constructed a prognostic model based on the expression profiles of JHDM1D-AS1 target genes from 18 cancer cohort studies from The Cancer Genome Atlas (TCGA) (330 bladder urothelial carcinoma \[BLCA\], 1,073 breast invasive carcinoma \[BRCA\], 236 cervical squamous cell carcinoma and endocervical adenocarcinoma \[CESC\], 147 esophageal carcinoma \[ESCA\], 163 glioblastoma multiforme \[GBM\], 465 head and neck squamous cell carcinoma \[HNSC\], 595 kidney renal clear-cell carcinoma \[KIRC\], 286 kidney renal papillary cell carcinoma \[KIRP\], 481 brain lower-grade glioma \[LGG\], 365 liver hepatocellular carcinoma \[LIHC\], 490 lung adenocarcinoma \[LUAD\], 468 lung squamous cell carcinoma \[LUSC\], 302 ovarian serous cystadenocarcinoma \[OV\], 152 pancreatic adenocarcinoma \[PAAD\], 208 sarcoma \[SARC\], 290 skin cutaneous melanoma \[SKCM\], 344 stomach adenocarcinoma \[[@B17]\], and 376 uterine corpus endometrial carcinoma \[UCEC\] samples). The JHDM1D-AS1 target genes were identified as differentially expressed genes in JHDM1D-AS1-overexpressed AsPC1 xenografts and a mock control and were called the "JHDM1D-AS1 signature" (see Table S3 in the supplemental material). We used a Lasso-regularized Cox proportional-hazard model to build a JHDM1D-AS1 signature-based prognostic classifier. The results of the Cox model in each cohort are summarized in [Table 2](#T2){ref-type="table"}. Among the 18 cohort studies, the Lasso using Akaike\'s information criterion (AICc) selected a null model with just a *y* intercept in 7 studies (BRCA, ESCA, HNSC, KIRP, LGG, OV, and SARC), which were not used in further analysis. For the other 11 cohort studies (BLCA, CESC, GBM, KIRC, LIHC, LUAD, LUSC, PAAD, SKCM, STAD, and UCEC), patients can be classified into two groups (high- and low-risk groups), and the difference in the survival between the two patient groups is significant (*P* value \[log rank test\] of \<0.01 for the 10 cohort studies) ([Fig. 7B](#F7){ref-type="fig"}), and it is also in the other cohorts ([Table 3](#T3){ref-type="table"}). These results indicated that JHDM1D-AS1 and its target genes were associated with overall survival in patients with several types of cancer.

###### 

Summary of the results for the Cox model in each cohort

  Tumor   Disease                                                            No. of samples   No. of genes selected by Cox model   *P* value (log rank)        
  ------- ------------------------------------------------------------------ ---------------- ------------------------------------ ---------------------- ---- -------------
  KIRC    Kidney renal clear cell carcinoma                                  595              49                                   546                    25   7.36E−14
  PAAD    Pancreatic adenocarcinoma                                          152              30                                   122                    25   1.68E−08
  SKCM    Skin cutaneous melanoma                                            290              195                                  95                     16   2.21E−07
  LIHC    Liver hepatocellular carcinoma                                     365              270                                  95                     31   3.56E−07
  GBM     Glioblastoma multiforme                                            163              42                                   121                    18   4.49E−06
  STAD    Stomach adenocarcinoma                                             344              282                                  62                     18   8.12E−06
  LUAD    Lung adenocarcinoma                                                490              204                                  286                    8    0.001342361
  LUSC    Lung squamous cell carcinoma                                       468              53                                   415                    7    0.003574324
  BLCA    Bladder urothelial carcinoma                                       330              302                                  28                     19   0.005061063
  CESC    Cervical squamous cell carcinoma and endocervical adenocarcinoma   236              178                                  58                     19   0.006150851
  UCEC    Uterine corpus endometrial carcinoma                               376              341                                  35                     11   0.054558634

###### 

Summary of the results of the Cox model in other cohorts

  Study      Platform   Cancer type   No. of samples   No. of genes selected by Lasso regularization using AICc   *P* value (log rank)   Corrected *P* value (false-discovery rate)              
  ---------- ---------- ------------- ---------------- ---------------------------------------------------------- ---------------------- -------------------------------------------- ---------- ----------
  GSE32062   GPL6480    Ovarian       260              51                                                         209                    22                                           2.28E−11   2.62E−10
  GSE30219   GPL570     Lung          289              230                                                        59                     21                                           4.04E−09   3.10E−08
  GSE1456    GPL97      Breast        159              64                                                         95                     8                                            6.06E−09   3.98E−08
  GSE22153   GPL6102    Skin          54               16                                                         38                     8                                            9.41E−09   5.41E−08
  GSE22762   GPL97      Heme          30               1                                                          29                     6                                            7.24E−08   3.33E−07
  GSE4412    GPL97      Brain         85               1                                                          84                     13                                           2.85E−07   1.09E−06
  GSE4271    GPL97      Brain         77               10                                                         67                     20                                           3.41E−07   1.21E−06
  GSE14333   GPL570     Colorectal    226              2                                                          224                    14                                           1.44E−06   4.74E−06
  GSE4922    GPL96      Breast        242              19                                                         223                    8                                            1.53E−05   4.68E−05
  GSE21501   GPL4133    Pancreas      102              67                                                         35                     9                                            3.12E−05   8.96E−05
  GSE42669   GPL6244    Brain         55               1                                                          54                     2                                            4.43E−05   0.000119
  GSE9195    GPL570     Breast        77               37                                                         40                     26                                           4.64E−05   0.000119
  GSE3494    GPL97      Breast        234              185                                                        49                     7                                            7.61E−05   0.000184
  GSE8842    GPL5689    Ovarian       82               48                                                         34                     30                                           0.000167   0.000384
  GSE17260   GPL6480    Ovarian       110              56                                                         54                     2                                            0.000263   0.000576
  GSE37418   GPL570     Brain         73               57                                                         16                     4                                            0.000428   0.000895
  GSE1379    GPL1223    Breast        60               35                                                         25                     3                                            0.000843   0.001687
  GSE13213   GPL6480    Lung          117              42                                                         75                     4                                            0.001022   0.001923
  GSE32063   GPL6480    Ovarian       40               33                                                         7                      4                                            0.001045   0.001923
  GSE17710   GPL9053    Lung          56               5                                                          51                     3                                            0.001087   0.001923
  GSE9893    GPL5049    Breast        155              18                                                         137                    3                                            0.001171   0.001994
  GSE18229   GPL887     Breast        53               1                                                          52                     4                                            0.001946   0.003197
  GSE425     GPL317     Breast        22               15                                                         7                      6                                            0.005002   0.007669
  GSE13041   GPL8300    Brain         49               46                                                         3                      4                                            0.007634   0.010973
  GSE3       GPL10      Adrenal       32               18                                                         14                     6                                            0.015127   0.021087
  GSE6532    GPL96      Breast        306              129                                                        177                    8                                            0.017094   0.023127
  GSE18229   GPL885     Breast        13               1                                                          12                     2                                            0.019016   0.023769
  GSE19234   GPL570     Skin          44               40                                                         4                      44                                           0.141582   0.155066
  GSE4412    GPL96      Brain         85               84                                                         1                      4                                            0.280437   0.293184
  GSE14814   GPL96      Lung          133              132                                                        1                      2                                            0.401377   0.410296

DISCUSSION {#sec3}
==========

We have shown that the lncRNA JHDM1D-AS1 is upregulated in response to nutrient starvation and that the subsequent increase in solid pancreatic tumor growth is associated with upregulation of genes for several proangiogenic factors, such as *HGF* and *FGF1*, and proinflammatory factors, such as *MMP*3, *MMP9*, *S100a8*, and *S100a9*, resulting in tumor progression.

Antisense lncRNAs are transcribed from the promoter regions of the coding gene and can be important not only for the expression of sense genes but also for the expression of distant genes under cellular stress, such as hypoxic conditions ([@B18], [@B19]). Here, we identified a long noncoding antisense transcript of JHDM1D, JHDM1D-AS1, whose expression levels increased under nutrient starvation in accordance with the levels of JHDM1D. The high expression of JHDM1D-AS1 in various cancer cell lineages and in patients suggests an important role of this lncRNA in cancer progression.

Many lncRNAs localize mainly in the nuclear fraction, which is critical for their role in chromatin remodeling in *cis* or *trans* ([@B2]). In the present study, fractionation analysis revealed that JHDM1D-AS1 is localized in both the cytosol and nucleus, similar to the case for coding mRNAs, suggesting a dual role of JHDM1D-AS1 in not only the nucleus but also the cytoplasm. In addition, JHDM1D-AS1 overexpression did not affect JHDM1D expression, suggesting that JHDM1D-AS1 may not function in *cis*. lncRNAs that are exported to the cytoplasm can interfere with protein posttranscriptional modification, alter gene expression by acting as a decoy for miRNA, and modulate mRNA translation ([@B20]). An important goal for future studies should be to determine the mechanisms underlying how JHDM1D-AS1 exerts its role in cancer cell growth.

Because JHDM1D-AS1 accelerated cell growth *in vitro*, we hypothesized that it could accelerate tumor growth *in vivo*. A xenograft study revealed that JHDM1D-AS1 overexpression indeed increased tumor growth *in vivo*, accompanied by elevated blood vessel formation and macrophage infiltration. Although overexpression of JHDM1D-AS1 had minor effects on cell growth *in vitro*, JHDM1D-AS1 overexpression resulted in a significant increase in tumor growth *in vivo*. We previously reported that overexpression and knockdown of the JHDM1D gene, the sense coding gene of JHDM1D-AS1, had minor effects on cell growth under growth-rich and nutrient starvation conditions *in vitro* but induced significant tumor growth *in vivo* by regulating angiogenesis ([@B11]). Thus, it is conceivable that JHDM1D-AS1 may also influence the tumor microenvironment rather than the cancer cells themselves.

Angiogenesis is orchestrated by various proangiogenic factors, such as VEGFs, FGFs, HGF, and the angiopoietin/Tie system, in addition to many other growth factors ([@B21], [@B22]). In the present study, microarray analysis and subsequent quantitative PCR revealed that JHDM1D-AS1-overexpressing AsPC-1 and PANC-1 cancer cells showed increased angiogenesis through upregulation of genes for angiogenic factors, including *HGF* and *FGF1*. We and others previously demonstrated that the nutrient-deprived tumor microenvironment and several long noncoding RNAs can promote tumor angiogenesis ([@B11], [@B19], [@B23][@B24][@B25]), but the specific lncRNAs involved in angiogenesis under nutrient starvation are not fully understood. To the best of our knowledge, this is the first report suggesting that an lncRNA responsive to nutrient starvation plays an important role in angiogenesis by modulating multiple angiogenic factors.

Interactions between cancer cells and the associated stroma as well as immune cells such as macrophages contribute to tumor angiogenesis and progression ([@B26]). In the present study, xenografting of JHDM1D-AS1-overexpressing cancer cells triggered inflammation in the surrounding host stromal cells by upregulation of inflammatory genes such as *Mmp3*, *Mmp9*, *S100a8*, and *S100a9*. Tumor-promoting inflammation is one of the hallmarks of cancer progression; thus, these data may explain why JHDM1D-AS1 overexpression had more impact on *in vivo* tumor growth than on *in vitro* cell proliferation. We and others have previously reported that infiltration of macrophage lineage cells associated with increased levels of host-derived MMP3, MMP9, S100A8, and S100A9 stimulated angiogenesis ([@B11], [@B14], [@B27]). Thus, JHDM1D-AS1 may promote tumor angiogenesis by secretion of proangiogenic factors and by stimulation of proangiogenic inflammation.

To identify the JHDM1D-AS1 direct or indirect target genes called the "JHDM1D-AS1 signature," we performed DNA microarray analysis of JHDM1D-AS1-overexpressed AsPC1 xenografts (case) and a mock control. As a result, a total of 237 probes corresponding to 150 genes were selected as differentially expressed genes in JHDM1D-AS1-overexpressing tumor tissues and used in further analysis. To assess the impact of JHDM1D-AS1-associated genes on prognosis in cancer patients, we conducted survival analysis using the Lasso-regularized Cox proportional-hazard model based on the expression profiles of the JHDM1D-AS1 signature in patients with various types of cancer. Remarkably, the prognostic model of JHDM1D-AS1-associated genes was classified into two groups (groups with worse and better prognosis), further supporting the clinical importance of JHDM1D-AS1.

In conclusion, our findings provide evidence that JHDM1D-AS1 is upregulated under nutrient starvation in the tumor microenvironment and accelerates tumor angiogenesis and growth *in vivo* by modulating expression of genes for angiogenic factors such as *HGF* and *FGF1* and triggering inflammation in the surrounding tumor microenvironment, thereby promoting malignancy of cancer. Based on these results, we suggest that inhibition of the nutrient starvation-responsive lncRNA JHDM1D-AS1 can be a potential therapeutic approach for cancer in the future.

MATERIALS AND METHODS {#sec4}
=====================

Cell culture, hypoxia, and nutrient starvation. {#sec4-1}
-----------------------------------------------

The human pancreatic carcinoma epithelial-like cell line PANC-1 and the adenocarcinoma ascites metastasis cell line AsPC-1 were purchased from the American Type Culture Collection (Manassas, VA). Cells were maintained in RPMI 1640 medium (Nacalai Tesque, Kyoto, Japan) and Dulbecco\'s modified Eagle\'s medium (DMEM) (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO~2~ atmosphere, respectively. Normal human dermal fibroblasts (NHDFs) and human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Tokyo, Japan) and maintained in fibroblast basal medium (FBM) or endothelial cell basal medium 2 (EBM2) (Lonza, Tokyo, Japan) at 37°C in a 5% CO~2~ atmosphere, respectively.

Nutrient deprivation medium was prepared to contain inorganic salts, i.e., 0.2 g/liter CaCl~2~ (anhydrous), 0.1 mg/liter Fe(NO~3~)~3~/9H~2~O, 0.4 g/liter KCl, 97.67 mg/liter MgSO~4~ (anhydrous), 6.4 g/liter NaCl, 3.7 g/liter NaHCO~3~, 0.125 g/liter NaH~2~PO~4~/H~2~O, and 15 mg/liter phenol red, according to the composition of DMEM. Then, 1% nutrient-containing medium was prepared from a mixture of the nutrient deprivation medium and the complete nutrient DMEM supplemented with 10% FBS at a ratio of 99:1. Cells were seeded in complete fresh medium for 20 h. The cells were then washed with phosphate-buffered saline (PBS), nutrient starvation was initiated by replacement with nutrient-deprived medium containing 1% nutrition, and cells were cultured for 24 h, unless otherwise stated, as previously described ([@B11], [@B28]).

Cell proliferation assay. {#sec4-2}
-------------------------

Cell proliferation was measured using the sulforhodamine B (SRB) assay as previously described ([@B28]).

Fractionation. {#sec4-3}
--------------

Cells (∼1 × 10^7^) were collected using a cell scraper and centrifuged at 500 × *g* for 5 min. The cell pellet was washed in ice-cold RSB150 buffer (10 mM Tris-HCl \[pH 7.4\], 150 mM NaCl, 2.5 mM MgCl~2~) and centrifuged. The cell pellet was resuspended in 400 μl of ice-cold RSB150 buffer, and then 0.25 mg/ml digitonin was added to the cells and incubated for 5 min on ice. The cells were centrifuged at 3,000 × *g* for 1 min at 4°C, yielding the cytoplasmic (supernatant) and nuclear (pellet) fractions. The supernatant was reserved on ice as a source of the cytoplasmic fraction. The nuclear pellet was washed twice in ice-cold RSB150 buffer and centrifuged. The nuclear pellet was resuspended in 400 μl of ice-cold RSB150 buffer and 0.5% Triton X-100. The obtained fractions were subjected to RNA extraction using TRIzol LS (Thermo Fisher Scientific, MA) in accordance with the manufacturer\'s instructions. Samples were eluted with 40 μl of RNase-free water for each fraction.

Gene expression analysis using real-time PCR. {#sec4-4}
---------------------------------------------

Total RNA was extracted from cells using the Isogen reagent (Nippon Gene, Toyama, Japan), converted to cDNA by using the Prime Script reverse transcriptase (TaKaRa, Shiga, Japan) as per the manufacturer\'s instructions, and used for quantitative real-time PCR amplification with SYBR green (TaKaRa) ([Table 4](#T4){ref-type="table"}).

###### 

qRT-PCR primers used in this study

  Primer            Forward sequence                  Reverse sequence
  ----------------- --------------------------------- ------------------------------------
  Human                                               
      *ACTB*        5′-AGAAGGAGATCACTGCCCTGGCACC-3′   5′-CCTGCTTGCTGATCCACATCTGCTG-3′
      *GAPDH*       5′-ACTTTGTCAAGCTCATTTCCTG-3′      5′-CTCTCTTCCTCTTGGCTCTTG-3′
      *BIRC5*       5′-GACCACCGCATCTCTACATTC-3′       5′-CCAAGTCTGGCTCGTTCTC-3′
      *S16*         5′-CCAAGTCTGGCTCGTTCTC-3′         5′-CAGGTCCAGGGGTCTTGGTCC-3′
      *MALAT1*      5′-CAGGTCCAGGGGTCTTGGTCC-3′       5′-ATTCGGGGCTCTGTAGTCCT-3′
      *Xist*        5′-CCCGTCTTTTGTTGGACAGT-3′        5′-GGATTCTCCAGAAGCACAGC-3′
      *TUG1*        5′-CAAGCACTACCACCAGCACTGTTAC-3′   5′-GCAATCAGGAGGCACAGGACATAAT-3′
      *VEGF-A*      5′-GCGGAGAAAGCATTTGTTTGT-3′       5′-CGGCTTGTCACATCTGCAAC-3′
      *VEGF-B*      5′-GATCCGGTACCCGAGCAGTCAG-3′      5′-CACCTGCAGGTGTCTGGGTTGA-3′
      *VEGF-C*      5′-CAGTGTCAGGCAGCGAACAA-3′        5′-CTTCCTGAGCCAGGCATCTG-3′
      *VEGF-D*      5′-ATCTGTATGAACACCAGCACCTC-3′     5′-TGGCAACTTTAACAGGCACTAAT-3′
      *PlGF*        5′-CCGGCTCGTGTATTTATTACCG-3′      5′-GGCAACCACTGTTCTCCAGAGC-3′
      *ANG1*        5′-CCTTCCAGCAATAAGTGGTAGTT-3′     5′-CAAACGGCTCCAGATTCA-3′
      *ANG2*        5′-GAGGCTGAGAATCAGACTGACA-3′      5′-TTACTGATAAACTTGCACATAACATTCT-3′
      *FGF1*        5′-CAGGGTCCTGGTCCTAAAGAG-3′       5′-TGCCTGAATGCTCAGGTAGAC-3′
      *FGF2*        5′-TGAATCACTAACTGACTGAAAATTG-3′   5′-GAAGGGTCTCCCGCATACT-3′
      *HGF*         5′-GGTGGCCCACTTGTTTGT-3′          5′-CATCCACGACCAGGAACA-3′
      *TSP-1*       5′-CTCTACCAGTGTCCTCCTCACC-3′      5′-TTGTGGCCAATGTAGTTAGTGC-3′
      *TSP-2*       5′-AGTTTGGGTCTGTGGACTTCAG-3′      5′-TTCCACATCACCACATAGAAGC-3′
      *JHDM1D*      5′-TATTCAGGGCATGCTGTCTATG-3′      5′-GGGATCCTGGAGAGAGTTTCTT-3′
      *JHDM1-AS1*   5′-TTGGAGTCTGGCTAAAGAGCA-3′       5′-CTGGGCTTCCTTCTTCATACC-3′
  Mouse                                               
      *Actb*        5′-TGACAGGATGCAGAAGGAGA-3′        5′-GCTGGAAGGTGGACAGTGAG-3′
      *Mmp3*        5′-TCAGTGGATCTTCGCAGTTG-3′        5′-AGGATGCCTTCCTTGGATCT-3′
      *Mmp9*        5′-AGACGACATAGACGGCATCC-3′        5′-GTGGTTCAGTTGTGGTGGTG-3′
      *S100a8*      5′-CCTTTGTCAGCTCCGTCTTC-3′        5′-CAAGGCCTTCTCCAGTTCAG-3′
      *S100a9*      5′-TCATCGACACCTTCCATCAA-3′        5′-AAAGGTTGCCAACTGTGCTT-3′

Gene expression profiling and statistical analysis. {#sec4-5}
---------------------------------------------------

For genome-wide transcription analysis, data were collected and analyzed with a GeneChip Scanner 3000 (Affymetrix, CA). The GeneChip data were analyzed using the Affymetrix GeneChip operating software v1.3 with MAS5 algorithms to obtain a signal value (GeneChip score) for each probe set. For global normalization, the average signal in an array was made equal to 100.

RNA-seq. {#sec4-6}
--------

RNA-seq reads were aligned to human transcriptome (UCSC gene) and genome (GRCh37/hg19) references using Burrows-Wheeler Aligner. After a transcript coordinate was converted to a genomic positions, an optimal mapping result was selected from either transcript or genome mapping by comparing the minimal edit distance to the reference. Local realignment was performed within an in-house short-reads aligner with a smaller *k*-mer size (*k* = 11). Finally, values for fragments per kilobase of exon per million fragments mapped (FPKM) were calculated for each UCSC gene while considering strand-specific information.

ChIP. {#sec4-7}
-----

PANC-1 cells (1 × 10^7^) were cross-linked with 1% formaldehyde for 10 min at room temperature. Fixation was stopped by adding 0.125 M glycine. Nuclear pellets were prepared for chromatin immunoprecipitation (ChIP) as described previously ([@B29]). Prewashed magnetic Dynabeads (Life Technologies, MA) were incubated with anti-H3K27ac antibody (Millipore, MA) or anti-SREBP2 antibody (Cayman, MI) in ChIP dilution buffer (20 mM Tris-HCl \[pH 8.0\], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitor cocktail \[Roche, Basel, Switzerland\]) for 6 h by wheel rotating at 4°C. Subsequently, sonicated cross-linked nuclear lysates were added and incubated overnight at 4°C by wheel rotating. The beads were washed several times and eluted with elution buffer (1% SDS and 100 mM NaHCO~3~), and the eluent was incubated with pronase (1 mg ml^−1^) at 42°C for 2 h and then incubated at 65°C overnight. DNA was purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany). ChIP-seq was done with an Illumina/Solexa sequencer as previously described ([@B29]).

ChIP-seq data processing. {#sec4-8}
-------------------------

All bound DNA fragments were mapped to the UCSC build hg19 (NCBI build 37) assembly of the mouse genome by using the mapping program ELAND (<http://support.illumina.com/sequencing/sequencing_software/casava.html>) based on the 50-side 36-bp sequences.

Formaldehyde-assisted isolation of regulatory elements. {#sec4-9}
-------------------------------------------------------

Formaldehyde-assisted isolation of regulatory elements was performed as described previously ([@B30]). Briefly, formalin-cross-linked cell pellets were lysed in SDS lysis buffer (50 mM Tris-HCl \[pH 8.0\], 10 mM ETDA, 1% SDS, and proteinase inhibitor cocktail \[Nacalai Tesque, Kyoto, Japan\]) and sonicated with an ultrasound homogenizer (Bioruptor UCD-200TM; Cosmo Bio). Samples were subjected to phenol-chloroform extraction twice followed by ethanol precipitation and subsequently were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany).

gRNAs. {#sec4-10}
------

Lentivirus CRISPR/Cas9 vectors targeting transcription start site (TSS) regions of JHDM1D-AS1 were constructed using lentiCRISPR v2 vectors (Addgene). Lentiviral particles containing gRNAs were produced using packaging (HEK293Ta) cells according to the manufacturer\'s instructions (Addgene). Cells were infected with the gRNA lentiviruses with 8 μg/ml Polybrene and subsequently selected using 2 μg/ml puromycin for forward gRNAs and 6 μg/ml blasticidin for reverse gRNAs ([Table 5](#T5){ref-type="table"}).

###### 

Guide RNAs used in this study

  Primer       Targeting type    Forward sequence                  Reverse sequence
  ------------ ----------------- --------------------------------- ---------------------------------
  Control      Not applicable    5′-GTCCCCTCCACCCCACAGTG-3′        5′-CACTGTGGGGTGGAGGGGAC-3′
  gRNA set 1   Promoter + exon   5′-AGAAGGAGATCACTGCCCTGGCACC-3′   5′-CCTGCTTGCTGATCCACATCTGCTG-3′
  gRNA set 2   Promoter + exon   5′-AGAAGGAGATCACTGCCCTGGCACC-3′   5′-TTATTTCGGAGCGAGAGCCG-3′
  gRNA set 3   Promoter + exon   5′-CTCCCCGCTCCTCTCCGCGA-3′        5′-TTATTTCGGAGCGAGAGCCG-3′

Retroviral transfection of JHDM1D-AS1. {#sec4-11}
--------------------------------------

A PMX-puro retroviral vector containing full-length human JHDM1D-AS1 was transfected by the pantropic platinum-GP retroviral packaging cell line (PlatGP) ([@B31]) using Fugene 6 transfection reagent (Roche). Target cells were infected overnight with the vesicular stomatitis virus (VSV)/Polybrene-containing supernatant. After infection, the colonies were selected in a medium containing 1.5 μg/ml puromycin.

Animal studies, tumor xenograft, and clinical samples. {#sec4-12}
------------------------------------------------------

Human PANC-1 and AsPC-1 cells (1 × 10^7^) were subcutaneously injected into Icr-scidJcl *scid/scid* mice. The tumor volume was measured, and the data were analyzed using Student\'s *t* test. All animal care procedures and patient experiments were in accordance with institutional guidelines approved by the University of Tokyo.

Immunofluorescence staining. {#sec4-13}
----------------------------

Freshly frozen or 4% paraformaldehyde (PFA)-fixed tumor tissues were cut 14 μm thick by using a Cryostat (Leica, Wetzlar, Germany) and stained with hamster anti-CD31 (BD Biosciences, San Jose, CA) and rat anti-CD11b (BD Biosciences). The sections were incubated with the appropriate secondary antibody and the nucleus-staining dye To-Pro-3 (Invitrogen Life Technologies, Tokyo, Japan) and then analyzed using a confocal microscope (Radiance 2000; Bio-Rad, CA). We quantified the number of CD31^+^ blood vessels/pericytes in the total area of the tumor. We analyzed 5 to 10 fields per sample (*n* = 5) for quantification of blood vessel density (*k* pixels). We also counted the CD11b^+^ cells in the total area of the tumor in 5 to 10 fields for each sample (*n* = 5).

siRNA. {#sec4-14}
------

siRNAs designed against human JHDM1D-AS1 were obtained commercially (Invitrogen Life Technologies, MA). In this study, two sequences of siRNAs were used against JHDM1D-AS1: siJHDM1D-AS1_1 (sense, 5′-GAACCCUUCCGAUUCCCAATT-3′; antisense, 5′-UUGGGAAUCGGAAGGGUUCAT-3′) and siJHDM1D-AS1_2 (sense, 5′-GCAUAUAUAUAGCGGGAAATT-3′; antisense, 5′-UUUCCCGCUAUAUAUAUGCCA-3′). Cells were transfected with JHDM1D-AS1 siRNAs or negative (scramble) control siRNA using Lipofectamine RNAi MAX transfection reagent according to the instructions of the manufacturer (Invitrogen Life Technologies). The ability of the siRNA to inhibit target gene expression was accessed 48 h posttransfection.

Survival analysis using the JHDM1D-AS1 signature. {#sec4-15}
-------------------------------------------------

By analyzing DNA microarray gene expression profiles of JHDM1D-AS1-overexpressed AsPC1 xenografts (case) and a mock control, a total of 237 probes corresponding to 150 genes were selected, whose average expression level in the case was upregulated more than 4 times compared to that in the control and upregulated more than 75th percentile in that in the case (see Table S3 in the supplemental material). The selected genes were considered direct or indirect target genes of JHDM1D-AS1 and called the "JHDM1D-AS1 signature." To construct the prognostic model for cancer patients based on the expression profiles of the JHDM1D-AS1 signature, we downloaded normalized RNA-seq expression data sets for 18 cancer cohort studies (330 bladder urothelial carcinoma \[BLCA\], 1,073 breast invasive carcinoma \[BRCA\], 236 cervical squamous cell carcinoma and endocervical adenocarcinoma \[CESC\], 147 esophageal carcinoma \[ESCA\], 163 glioblastoma multiforme \[GBM\], 465 head and neck squamous cell carcinoma \[HNSC\], 595 kidney renal clear-cell carcinoma \[KIRC\], 286 kidney renal papillary cell carcinoma \[KIRP\], 481 brain lower-grade glioma \[LGG\], 365 liver hepatocellular carcinoma \[LIHC\], 490 lung adenocarcinoma \[LUAD\], 468 lung squamous cell carcinoma \[LUSC\], 302 ovarian serous cystadenocarcinoma \[OV\], 152 pancreatic adenocarcinoma \[PAAD\], 208 sarcoma \[SARC\], 290 skin cutaneous melanoma \[SKCM\], 344 stomach adenocarcinoma \[[@B17]\], and 376 uterine corpus endometrial carcinoma \[UCEC\] samples) from the Broad TCGA GDAC website (<http://gdac.broadinstitute.org/>). We then used a Lasso-regularized Cox proportional-hazard model with the glmnet package (version 2.0-5) ([@B32]) in the R statistical environment (version 3.3.2) to build a JHDM1D-AS1 signature-based prognostic classifier. The tuning parameter λ in the Lasso regularization was chosen by using the corrected Akaike\'s information criterion (AICc) ([@B33], [@B34]). The results of the Cox model in each cohort are summarized in [Table 2](#T2){ref-type="table"}. Among the 18 cohort studies, the Lasso using AICc selected a null model with just an *y* intercept in 7 studies (BRCA, ESCA, HNSC, KIRP, LGG, OV, and SARC), which were not used in further analysis. For the other 11 cohort studies (BLCA, CESC, GBM, KIRC, LIHC, LUAD, LUSC, PAAD, SKCM, STAD, and UCEC), patients were classified into two groups based on whether the risk score in the Cox model was more than 0 (high risk and worse prognosis) or less than 0 (low risk and better prognosis). To evaluate the prognostic significance of the Cox model, we used the Kaplan-Meier method, and the *P* value was calculated using the log rank test. For adjustment for multiple hypothesis testing, the *P* values were corrected by the Benjamini-Hochberg procedure ([@B35]).

Supplementary Material
======================

###### Supplemental material

Supplemental material for this article may be found at <https://doi.org/10.1128/MCB.00125-17>.
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